NMDP-02 is under clinical development by NMD Pharma and currently in Phase I for Spinal Muscular Atrophy (SMA). According to GlobalData, Phase I drugs for Spinal Muscular Atrophy (SMA) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NMDP-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMDP-02 overview

NMDP-02 is under development for the treatment of spinal muscular atrophy type 3. It acts by targeting chloride channel protein 1 (CLC-1). It is administered through oral route.

NMD Pharma overview

NMD Pharma discovers and develops small molecule drugs for the treatment of neuromuscular disorders. It develops novel treatments that strengthen neuromuscular transmission and muscle function. NMD Pharma offers services to patients with loss of muscle functionality resulting in reduced mobility and to patients with muscle weakness resulting in life-threatening respiratory problems. The company is also developing small molecules, which increase neuromuscular transmission and treat orphan diseases including myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. NMD Pharma is headquartered in Aarhus, Denmark.

For a complete picture of NMDP-02’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.